Stock Events

Stock Events

Collegium Pharmaceutical 

$28.74
49
+$0.24+0.84% Wednesday 20:00
+$0.00+0%Wednesday 20:00After hours

Statistics

Day High
28.77
Day Low
28.68
52W High
50.79
52W Low
25.47
Volume
17,829
Avg. Volume
-
Mkt Cap
890.92M
P/E Ratio
17.1
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
1.43
1.71
1.98
2.25
Expected EPS
1.90325
Actual EPS
N/A

Financials

8.05%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
780.57MRevenue
62.87MNet Income

Analyst Ratings

49.25Average Price Target
The highest estimate is 60.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COLL. It's not an investment recommendation.
NVIDIA
8
NVDA
Amazon
7
AMZN
Microsoft
6
MSFT
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.85B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly in the pain management market where Collegium also operates.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in various therapeutic areas including pain management, directly overlapping with Collegium's market.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the specialty pharmaceuticals space, including pain management with its products, which positions it as a competitor to Collegium.
AMGEN
AMGN
Mkt Cap224.63B
Amgen, a biotechnology company, has a portfolio that includes treatments for pain, making it a competitor in some of Collegium's key markets.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. competes across a broad range of therapeutic areas, including pain management through its innovative and generic drug offerings.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is a global pharmaceutical company with a diverse portfolio, including pain management solutions that compete with Collegium's products.
Pacira BioSciences
PCRX
Mkt Cap916.82M
Pacira Biosciences focuses on non-opioid pain management solutions, offering competitive alternatives to Collegium's opioid-based pain management products.

About

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Show more...
CEO
Vikram Karnani
Employees
423
Country
United States
ISIN
US19459J1043
WKN
000A14SUV

Listings

STU
DE
354.STU
MU
DE
354.MU
XNAS
US
COLL
F
DE
354.F

0 Comments

Share your thoughts

FAQ

What is Collegium Pharmaceutical stock price today?▼
The current price of COLL is $28.74 USD — it has increased by +0.84% in the past 24 hours. Watch Collegium Pharmaceutical stock price performance more closely on the chart.
What is Collegium Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Collegium Pharmaceutical stocks are traded under the ticker COLL.
Is Collegium Pharmaceutical stock price growing?▼
COLL stock has risen by +2.1% compared to the previous week, the month change is a -19.13% fall, over the last year Collegium Pharmaceutical has showed a -25.1% decrease.
What is Collegium Pharmaceutical market cap?▼
Today Collegium Pharmaceutical has the market capitalization of 890.92M
When is the next Collegium Pharmaceutical earnings date?▼
Collegium Pharmaceutical is going to release the next earnings report on November 05, 2026.
What were Collegium Pharmaceutical earnings last quarter?▼
COLL earnings for the last quarter are 1.92 USD per share, whereas the estimation was 1.72 USD resulting in a +11.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Collegium Pharmaceutical revenue for the last year?▼
Collegium Pharmaceutical revenue for the last year amounts to 780.57M USD.
What is Collegium Pharmaceutical net income for the last year?▼
COLL net income for the last year is 62.87M USD.
How many employees does Collegium Pharmaceutical have?▼
As of August 20, 2026, the company has 423 employees.
In which sector is Collegium Pharmaceutical located?▼
Collegium Pharmaceutical operates in the Health & Wellness sector.
When did Collegium Pharmaceutical complete a stock split?▼
Collegium Pharmaceutical has not had any recent stock splits.
Where is Collegium Pharmaceutical headquartered?▼
Collegium Pharmaceutical is headquartered in STOUGHTON, United States.